• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Aug 2006; 65(8): 1116–1117.
PMCID: PMC1798243

Successful use of rituximab in a patient with recalcitrant Churg‐Strauss syndrome

Churg‐Strauss syndrome (CSS) is a disorder characterised by hypereosinophilia and systemic vasculitis occurring in people with asthma and allergic rhinitis. Corticosteroids in combination with a cytotoxic agent are the most effective treatment for CSS. Rituximab, a genetically engineered chimeric anti‐CD20 monoclonal antibody has recently been tried with favourable responses in chronic immunological diseases.1 Several published reports have shown its effectiveness in ANCA mediated vasculitides.2,3 We present a patient with CSS who responded well to rituximab after conventional treatments had failed.

A 49 year old, white male patient with a long history of asthma presented in 2000 with inflammatory polyarthritis, bilateral scleritis, and negative autoantibodies. He was managed as a patient with seronegative RA but was intolerant to methotrexate and sulfasalazine. His symptoms settled, only to recur in 2004 with polyarthralgia, vasculitic skin rash (fig 11),), dyspnoea, microscopic haematuria, and mild proteinuria.

figure ar47308.f1
Figure 1 Skin vasculitic changes before (above) and after (below) treatment with rituximab.

Repeat investigations showed a high absolute eosinophil count of 4×109/l, raised erythrocyte sedimentation rate (ESR) of 120 mm/1st h, and C reactive protein (CRP) of 181 mg/l, mildly raised creatinine, and a positive cANCA (anti‐proteinase 3 (PR3) titre of 30 (normal <2)). High resolution computed tomography of his chest showed pulmonary infiltrates consistent with pulmonary vasculitis. A nasal biopsy showed chronic inflammation, with some areas suggestive of vasculitis, and eosinophilic infiltration. His skin biopsy showed leucocytoclastic vasculitis, and a renal biopsy disclosed minimal non‐specific abnormalities. Based on the above,4 a diagnosis of CSS was made and treatment was started with prednisolone 40 mg and azathioprine.

His initial response was not sustained, requiring a change to cyclophosphamide in January 2005. Despite fortnightly pulses of cyclophosphamide (15 mg/kg) for 5 months, his condition continued to deteriorate. At this point, after reviewing the available publications on the use of rituximab in ANCA associated vasculitis,2,3 treatment was started with this drug. Although it was planned as a 4 week regimen at 700 mg/week (375 mg/m2 body surface area) with 100 mg intravenous methylprednisolone,2 he required hospital admission after the second infusion, with bronchopneumonia and herpes zoster. This was treated appropriately, and his third infusion was given as a bolus on the 4th week (1 g). After this, his skin vasculitis cleared completely (fig 11)) with normal ESR, CRP, absolute eosinophil count, anti‐PR3 titres (fig 22),), and undetectable B cells with normal T cell markers. He has been seen fortnightly since then (nearly 3 months), with no recurrence of skin vasculitis. Small increases in his eosinophil count ((0.5–1.5) × 109/l) have occurred and treatment with oral prednisolone at a dose of 30 mg a day is continuing.

figure ar47308.f2
Figure 2 Changes to inflammatory markers and eosinophil count with rituximab (indicated by arrows)

Based on the above, rituximab appears to be a promising treatment for induction of remission in CSS. The rationale behind the use of rituximab is based on three assumptions5: (a) ANCA has an important role in the pathogenesis of ANCA associated vasculitides; (b) treatment with rituximab can effectively deplete CD20 expressing precursors of ANCA‐producing plasma cells; and (c) plasma cells producing ANCA are short lived, and transient depletion of their CD20+ precursors will abrogate ANCA production. However, we need to be aware of the concurrent risks of robust immunosuppression and predisposition to serious infections. Further research is warranted into the maintenance of remission and the long term safety with rituximab use.

Footnotes

Accepted 17 March 2006

Conflict of interest: None

References

1. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti‐CD20 therapy of treatment‐resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005. 34229–232.232 [PubMed]
2. Eriksson P. Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab. J Intern Med 2005. 257(540–548.548 [PubMed]
3. Specks U, Fervenza F C, McDonald T J, Hogan M C. Response of Wegener's granulomatosis to anti‐CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001. 442836–2840.2840 [PubMed]
4. Masi A T, Hunder G G, Lie J T, Michel B A, Bloch D A, Arend W P. et al The American College of Rheumatology 1990 criteria for the classification of Churg‐Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990. 331094–1100.1100 [PubMed]
5. Sneller M C. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 2005. 521–5.5 [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...